NeuroMab™ Anti-HMGB1 BBB Shuttle Antibody,Clone NR3503P
- Host Species:
- Human
- Species Reactivity:
- Human
- Applications:
- WB; In Vitro; In Vivo
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Relevant Diseases
Storage
Research Use Only
Target
Official Name
Full Name
Alternative Names
Figure 1 shows the results of detection of human HMGB1 protein by Western blotting using human monoclonal antibodies.
"#127", "#129", "#194", "#459", "#130-008", "#213-012", "#213-001", "#283-010" in the picture , "#370-010" indicates the result of using a human monoclonal antibody as the primary antibody.
Figure 2 shows the results of surface plasmon resonance spectroscopy (SPR) detection of the interaction between a human monoclonal antibody (mAb #127) and human HMGB1 protein.
As a result of the analysis, the dissociation constant (KD) of monoclonal antibody #127 was 2.17×10-11 M, indicating that the antibody has extremely high affinity.
Figure 3 shows the detection results of the human MARCKS phosphorylation inhibitory activity of the human monoclonal antibody.
Figure 4 shows the effect of subcutaneous administration of the human monoclonal antibody (monoclonal antibody #129) on cognitive function and dendritic spine density in Alzheimer's disease model mice.
Fig. 1 shows the results of quantification of the cognitive function of each drug administration group by the Y-maze test.
Figure 5 shows the effect of subcutaneous administration of the human monoclonal antibody (monoclonal antibody #129) on cognitive function and dendritic spine density in Alzheimer's disease model mice.
Synapses (dendritic spines) revealed after imaging with two-photon excitation microscopy.
Figure 6 shows the effect of subcutaneous administration or intravenous injection of the human monoclonal antibody (monoclonal antibody #129) on the cognitive function of Alzheimer's disease model mice.
Fig. 1 shows the results of quantification of the cognitive function of each drug administration group by the Y-maze test. In the figure, "sc" represents subcutaneous injection, and "iv" represents intravenous injection. "B6/SJL" in the figure represents B6/SJL non-transgenic mice (normal mice), and "5xFAD" represents 5xFAD transgenic mice.
Figure 7 shows the localization of mAb #129 in the brain tissue of mice administered subcutaneously (sc injection) or intravenously (iv injection) of mAb #129. In the figure, "not injected" indicates the result of staining normal mouse brain without administration of antibody.
Publications (0)
